加强拉丁美洲药物警戒:两届ISoP拉美分会研讨会的多学科见解
本文总结了ISoP拉美分会在哥伦比亚卡塔赫纳(2023)和墨西哥梅里达(2025)举办的两届区域研讨会。研讨会汇集监管机构、学术界、医疗专业人员、研究者和患者组织等多方,讨论监管协调、国际标准采纳、人工智能与真实世界证据整合、用药错误的人因/工效学方法、生物类似药监管及治疗失败识别框架等议题,强调药物警戒教育和药学服务扩展的重要性。
要点
- 拉美药物警戒在监管框架和区域合作方面取得进展,但国家间异质性和资源不均仍限制其公共卫生影响。
- ISoP LATAM通过多学科论坛推动监管协调、国际标准采纳及人工智能和真实世界证据整合。
- 优先事项包括人因/工效学方法处理用药错误、生物类似药监管、治疗失败识别框架及药物警戒教育。
核心结论
- ISoP LATAM为拉美地区提供了开放的多学科讨论平台,推动药物警戒从单纯监管议题转向更广泛的公共卫生视角。
- 将药物基因组学、生态药物警戒和患者参与等新兴领域纳入议程,对提升拉美药物安全至关重要。
研究设计与样本
- 本文为两届ISoP拉美分会区域研讨会的多学科见解总结,分别于2023年在哥伦比亚卡塔赫纳和2025年在墨西哥梅里达举办。
- 研讨会通过多学科圆桌和开放论坛,汇集监管机构、学术界、医疗专业人员、研究者、患者组织和行业代表。
主要发现
- 拉美药物警戒在监管框架、区域合作和学术参与方面取得显著进展,但国家间异质性和机构发展不均仍阻碍其全面影响。
- 讨论涉及监管协调与趋同、风险管理和安全报告国际标准的采纳,以及人工智能和真实世界证据在药物警戒系统中的整合。
- 参与者强调以人因/工效学方法处理用药错误、加强生物类似药监测与监管、建立治疗失败识别的差异化框架。
- 扩展药学服务和将药物警戒教育系统纳入健康科学课程被列为优先事项。
临床怎么用
- 临床药学智能体可关注拉美地区监管协调动态及国际安全报告标准的采纳,以支持跨境药物安全信息处理。
- 在用药错误管理中引入人因/工效学视角,并关注生物类似药的监测与治疗失败识别框架。
- 重视药物警戒教育在健康科学课程中的系统整合,并探索人工智能和真实世界证据在药物警戒中的应用。
局限性
- 本文为研讨会见解总结,未报告系统检索方法、样本量或定量研究数据。
- 拉美地区国家间异质性和机构发展不均可能限制研讨会建议的普遍适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacovigilance in Latin America has witnessed notable progress in recent years, marked by advancements in regulatory frameworks, regional cooperation, and increased academic involvement. However, heterogeneity among countries, uneven institutional development, and limited resources still hinder its full impact on public health. In this context, the Latin American Chapter of the International Society of Pharmacovigilance (ISoP LATAM) has played a key role in organizing two regional symposia: Cartagena, Colombia (2023), and Merida, Mexico (2025). Through multidisciplinary roundtables and open forums, ISoP LATAM has brought together regulators, academia, healthcare professionals, researchers, patient organizations, and industry representatives to promote dialogue, identify opportunities, and propose measures to improve pharmacovigilance in the region. Discussion included regulatory harmonization and convergence, the adoption of international standards for risk management and safety reporting, and the integration of artificial intelligence and real-world evidence into pharmacovigilance systems. Participants emphasized the importance of addressing medication errors through a Human Factors/Ergonomics approach, strengthening the monitoring and regulation of biosimilars, and creating differentiated frameworks for recognizing therapeutic failures. The expansion of pharmaceutical care and the systematic inclusion of pharmacovigilance education across the health sciences' curriculum were highlighted as priorities. The reflections from these symposia emphasize the crucial role of ISoP LATAM in providing a platform for open and multidisciplinary discussions. Shifting the focus from solely regulatory topics to a broader public health perspective and expanding the agenda to include emerging fields such as pharmacogenomics, ecopharmacovigilance, and patient engagement-while ensuring fair access to technological innovations-will be vital for enhancing drug safety in Latin America.
引用
- Vargas-Neri JL, Caro-Rojas A, Castañeda-Hernández G, et al. Strengthening Pharmacovigilance in Latin America: Multidisciplinary Insights from Two ISoP Latin American Chapter Symposia. Drug Saf. 2026. PMID: 41863709. doi:10.1007/s40264-026-01662-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。